First Patient in the U.S. Receives Corcym's Perceval Plus® LANCELOT Valve in Groundbreaking Procedure

Groundbreaking Moment in Cardiac Surgery

In a significant development in the field of cardiac surgery, a patient in the United States has become the inaugural recipient of Corcym's advanced Perceval Plus® LANCELOT sutureless aortic valve. This historic procedure marks an important leap forward in the evolution of surgical valve replacement and showcases the progressive technologies that are continuously enhancing patient care in cardiac procedures.

The incorporation of the Perceval Plus® LANCELOT valve into surgical practices is built upon the established success of Corcym's Perceval platform, which has been effectively utilized by cardiac surgeons globally for nearly two decades. This new valve, utilizing a next-generation manufacturing process, boasts improved durability and performance that are crucial for patient outcomes during aortic valve replacement surgeries.

Surgical Procedure Overview

The pioneering surgical procedure took place in September 2025, conducted by a skilled U.S. cardiac surgery team. The innovative valve features precision laser-cut bovine pericardial leaflets that optimize its structure, potentially enhancing the accuracy of blood flow while maintaining the procedural efficiency of the sutureless platform. With such advancements, surgeons are equipped to provide higher levels of care while ensuring that surgeries remain less invasive for patients.

Following the successful implantation, the patient has made a remarkable recovery, quickly returning to everyday activities such as biking and spending quality time with family. This recovery includes emotional milestones, such as preparing to walk his daughter down the aisle—a testament to the effectiveness of this advanced surgical intervention.

Dr. Robert Gallegos, the Chief of Cardiac Surgery at CHI Health and a proctor for the procedure, pointed out that advances like the Perceval Plus® LANCELOT valve expand surgical options for patients diagnosed with aortic valve diseases. Similarly, Dr. Ali J. Khiabani, a Cardiac Surgeon at CHI Health, emphasized that innovations in valve design can significantly improve valve performance, which in turn enhances the overall procedural outcomes and long-term health of patients undergoing bioprosthetic aortic valve replacement.

A Commitment to Innovation

Christian Mazzi, CEO of Corcym, expressed that the initial U.S. implantation of the Perceval Plus® LANCELOT valve aligns with the company's mission of patient-centered innovation. He stated, "At Corcym, innovation begins and ends with the patient," highlighting the company's commitment to advancing surgical technologies that not only support cardiac surgeons but also drive better patient outcomes for those suffering from structural heart disease.

This implantation is a pivotal moment for not just the patient and the surgical team, but for the broader medical community as it embraces the potential of sutureless surgical techniques. By simplifying surgical procedures and reinforcing the minimally invasive approaches to heart surgeries, the Perceval platform empowers cardiac surgeons with the tools necessary to change lives.

Future Implications

As Corcym continues to develop and enhance its portfolio of surgical heart valve solutions, the Perceval Plus® LANCELOT valve stands out as a significant step forward in the journey to address this vital aspect of cardiac care. For nearly two decades, the Perceval platform has set a standard in the cardiac surgery landscape, and the introduction of the next-generation LANCELOT valve is expected to solidify its position as a leader in the field.

About Corcym

Corcym is a globally recognized medical device company that concentrates exclusively on cardiac solutions, empowering surgeons with the best technologies to fight structural heart disease. With a robust history of partnership with cardiac specialists and a diverse portfolio of techniques and tools for both open-heart and minimally invasive surgeries, Corcym is committed to revolutionizing the way heart diseases are treated. For more information, visit Corcym's website.